Quantcast

Latest Docosahexaenoic acid Stories

2014-06-11 12:28:43

WOODBRIDGE, ON, June 11, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that it retained Kilmer Lucas Inc. to provide it with Canadian and U.S. investor relations and strategic advisory services. "As we begin to fully execute our growth strategy, we are confident that Kilmer Lucas is the right...

2014-05-30 16:25:12

WOODBRIDGE, ON, May 30, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF) (CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated. Financial Results For the three months ended March 31, 2014,...

2014-05-15 12:37:30

Supplementation in Addition to Food Sources Could Help U.S. Adult Population Meet Omega-3 Fatty Acid Consumption Recommendations NORTHRIDGE, Calif., May 15, 2014 /PRNewswire/ -- A study published in the Nutrition Journal concludes that a large percent of the U.S. adult population is not meeting recommendations for omega-3 fatty acid consumption set for by the Dietary Guidelines for Americans (DGA). The Pharmavite supported study examined the intake of total fish, fish high in omega-3...

2014-05-14 20:23:53

WOODBRIDGE, ON, May 14, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF)(CSE:PVO) ("Pivotal" or "the Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, today announced changes to its Board designed to increase its independence and enhance Pivotal's corporate governance at this stage of the Company's development. Dr. Jackowski has stepped down as Chairman of Pivotal Therapeutics Inc. effective May...

2014-05-13 16:27:44

WOODBRIDGE, ON, May 13, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced that it has engaged Brandkarma LLC., an award winning, US-based, healthcare marketing and brand specialist with global expertise to support the Company's commercialization strategy for VASCAZEN(®). "VASCAZEN(®) represents a much-needed solution for...

2014-05-07 12:30:30

WOODBRIDGE, ON, May 7, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent Number 8,715,648 titled "Formulations Comprising Omega-3 Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight in Cardiovascular Disease Patients (CVD) and Diabetics"....

2014-05-06 23:10:48

Baby's DHA from Nordic Naturals now bears the title of the Official Baby's Omega-3 of the American Pregnancy Association. Watsonville, CA (PRWEB) May 06, 2014 Nordic Naturals’ Baby’s DHA, the number-one selling baby’s omega-3 in the U.S., has been named the “Official Baby’s Omega-3” by the American Pregnancy Association (APA). A non-profit national health organization, APA is committed to promoting reproductive and pregnancy wellness through education, support,...

2014-05-06 16:31:55

WOODBRIDGE, ON, May 6, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it presented two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions held in Toronto, Ontario, Canada, May 1-3, 2014. Both posters discussed Omega-3 deficiency (OM3D)...

2014-05-01 16:31:22

WOODBRIDGE, ON, May 1, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it will be presenting two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions in Toronto, Ontario, Canada, May 1-3, 2014. The first poster entitled "Correlation...

2014-05-01 16:31:16

WOODBRIDGE, ON, May 1, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announces a correction to its press release issued yesterday entitled "Pivotal Therapeutics Announces 2013 Financial Results". The decrease in the loss from 2012 to 2013 of $745,342 was inadvertently overstated by $91,520. The correct decrease in loss is $653,822 and...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.